Neurolieve Biosciences Ltd

Neurolieve Biosciences Limited, headquartered in London, UK, is developing a novel drug therapy, Fc13-GalR2, addressing patients suffering from Chemotherapy-induced peripheral neuropathy (CIPN), as primary target indication, thanks to a collaboration between University of Bristol and Life Arc, a prominent research and medical charity organization in the UK, and NLC Health Ventures located in Amsterdam.